Lee K-H, Lee J-H, Choi S-J, Lee J-H, Kim S, Seol M, Lee Y-S, Kim W-K, Lee J-S
Section of Hematology, Department of Internal Medicine, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea.
Bone Marrow Transplant. 2004 Apr;33(7):729-34. doi: 10.1038/sj.bmt.1704428.
The outcomes of patients who experience the failure to reconstitute a trilineage of blood cells after initial neutrophil engraftment were evaluated in 178 patients with hematologic disorders, who underwent allogeneic HCT. Of 165 qualified patients (five with primary engraftment failure; eight deaths before day 60 of HCT), 43 (26%) satisfied the criteria for the initial (n=22; failure of platelet >20 000/microl or red blood cell transfusion independence/reticulocyte count >/=1.0% by day 60) or subsequent (n=21, ANC <500/microl for >/=3 days, platelet <20 000/microl for >/=7 days, or red blood cells transfusion/reticulocyte <1.0% after initial trilineage reconstitution) failure. GVHD was the most common clinical condition associated with cytopenia (n=24). In all, 20 patients (47%) recovered at least partially with a median of 52 days (range 8-323) later, with 12 of those 20 patients recovering completely. The eventual reconstitution failure rate was 14% (23/163 patients). The number of cell lineages involved in the cytopenia was the only independent variable that predicted partial recovery (1 lineage vs 2-3 lineages with odds ratio of 8.69 (95% CI 1.96-38.60), P=0.004). Five/20 patients with vs 20/23 patients without partial recovery died. Trilineage reconstitution failures after allogeneic HCT need systematic analysis in the future studies.
对178例接受异基因造血细胞移植(HCT)的血液病患者,评估其在初始中性粒细胞植入后未能重建三系血细胞的患者结局。在165例合格患者中(5例原发性植入失败;8例在HCT第60天前死亡),43例(26%)符合初始(n = 22;血小板>20000/μl失败或红细胞输注独立性/网织红细胞计数在第60天时≥1.0%)或后续(n = 21,中性粒细胞绝对值(ANC)<500/μl≥3天,血小板<20000/μl≥7天,或初始三系重建后红细胞输注/网织红细胞<1.0%)失败的标准。移植物抗宿主病(GVHD)是与血细胞减少相关的最常见临床情况(n = 24)。总共20例患者(47%)至少部分恢复,中位恢复时间为52天(范围8 - 323天),其中20例患者中有12例完全恢复。最终重建失败率为14%(23/163例患者)。血细胞减少涉及的细胞系数量是预测部分恢复的唯一独立变量(1个细胞系与2 - 3个细胞系,优势比为8.69(95%可信区间1.96 - 38.60),P = 0.004)。部分恢复的5/20例患者与未部分恢复的20/23例患者死亡。异基因HCT后的三系重建失败在未来研究中需要系统分析。